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Abstract 
Aberrant embryonic development of the hypothalamus and/or pituitary gland in humans 
results in congenital hypopituitarism (CH). TCF7L1, an important regulator of the 
WNT/β-catenin signaling pathway, is expressed in the developing forebrain and pituitary 
gland but its role during hypothalamo-pituitary (HP) axis formation or involvement in 
human CH remains elusive. Using a conditional genetic approach in the mouse, we first 
demonstrate that TCF7L1 is required in the prospective hypothalamus to maintain normal 
expression of the hypothalamic signals involved in the induction and subsequent 
expansion of Rathke’s pouch progenitors. Next, we reveal that the function of TCF7L1 
during HP axis development depends exclusively on its repressing activity and does not 
require its interaction with β-catenin. Finally, we report the identification of two 
independent missense variants in human TCF7L1, p.R92P and p.R400Q, in a cohort of 
patients with forebrain and/or pituitary defects. We demonstrate that these variants 
exhibit reduced repressing activity in vitro and in vivo relative to wild-type TCF7L1. 
Together, our data provide support for a conserved molecular function of TCF7L1 as a 
transcriptional repressor during HP axis development in mammals and identify variants 
in this transcription factor that are likely to contribute to the etiology of CH. 
  
	   3	  
Significance Statement 
The relevance of TCF7L1 during hypothalamo-pituitary (HP) axis development remains 
unknown. Using mouse genetics, we show that TCF7L1 acts as a transcriptional repressor 
to regulate the expression of the hypothalamic signals involved in pituitary formation. In 
addition, we screened a cohort of human patients with forebrain and/or pituitary defects 
and report two independent novel missense variants, p.R92P and p.R400Q, in human 
TCF7L1. Functional studies in vitro and rescue experiments in zebrafish mutants 
deficient for tcf7l1a and tcf7l1b, show that the p.R92P and p.R400Q variants exhibit 
reduced repressing activity compared with wild-type TCF7L1.  In summary, we 
identify TCF7L1 as a novel determinant for the establishment of HP axis development 
and as a potential candidate gene to be mutated in congenital hypopituitarism.   
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\body 
Introduction 
Congenital hypopituitarism (CH) is a complex condition defined by the deficiency of one 
or more pituitary hormones, and can be present in isolation or as part of a syndrome (1-
3). Septo-optic dysplasia (SOD) is a rare form of CH (1 in 10,000) that manifests in 
conjunction with defects in the telencephalon (e.g. corpus callosum and septum 
pellucidum) and/or eyes (e.g. optic nerve hypoplasia), and is associated with high 
morbidity and occasional mortality (4). 
Abnormal embryonic development of the Hypothalamo-Pituitary (HP) axis is a 
major cause of CH. The pituitary gland, comprising the anterior and posterior lobes, is an 
organ of dual embryonic origin, and derives from oral and neural ectodem respectively. 
In the mouse at around 9.5 days post coitum (dpc), secreted signals from the 
hypothalamic primordium such as FGF8, FGF10, BMP4 and SHH induce Rathke’s 
pouch (RP), the primordium of the anterior pituitary (5, 6). Upon specification, RP 
progenitors proliferate rapidly, exit the cell cycle and activate the expression of cell fate 
commitment genes such as Pou1f1 (Pit1), Tpit and Sf1. This culminates in the 
differentiation of all hormone-producing cells by the end of gestation (7, 8); 
somatotrophs (growth hormone, GH), lactotrophs (prolactin, PRL), thyrotrophs (thyroid-
stimulating hormone, TSH), gonadotrophs (follicle-stimulating hormone, FSH and 
lutenizing hormone, LH), corticotrophs (adrenocorticotropic hormone, ACTH) and 
melanotrophs (melanocyte-stimulating hormone, MSH) (2, 9). A small proportion of cells 
remain in the postnatal anterior pituitary as tissue-specific stem cells, which have the 
capacity to self-propagate and differentiate in vivo and in vitro (10-12).  
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Mutations in several developmental genes regulating HP development in the 
mouse have been identified in patients suffering from CH and SOD (4). One of these is 
the homeobox gene Hesx1/HESX1, which acts as a transcriptional repressor of the 
WNT/β-catenin signaling pathway (13, 14). 
The stability of β-catenin, which is a strong transcriptional activator devoid of a 
DNA binding domain, is critical for normal WNT/β-catenin function (15-17). In the 
absence of WNT ligands, β-catenin is phosphorylated by a destruction complex and 
degraded rendering the pathway inactive (18, 19). The binding of WNT ligands leads to 
β-catenin dephosphorylation and stabilization (20, 21). It can then translocate into the 
nucleus and interact with mainly, but not exclusively, members of the T-cell 
factor/lymphoid enhancer factor (TCF/LEF) family to activate the expression of target 
genes (22, 23). In mammals, TCF/LEF factors include TCF7 (formerly TCF1), TCF7L1 
(formerly TCF3), TCF7L2 (formerly TCF4) and LEF1, which all bind the same 
consensus DNA motif 5’-(A/T)(A/T)CAAAG-3’ and have a β-catenin-interacting domain 
at the N-terminus (24, 25). It is believed that, in the absence of stable β-catenin, 
TCF/LEF factors can repress target genes of the pathway through interactions with co-
repressors (26, 27), although cell context-specific functions have been demonstrated 
where specific factors are mostly required as either activators (28, 29) or repressors (30-
33). 
In the developing HP axis, this pathway coordinates proliferation of RP 
progenitors and differentiation of hormone-producing cells (34-41). TCF7L1 has been 
shown to play critical roles in maintenance of stem cell pluripotency (42, 43), tissue 
homeostasis of the skin epithelia (44), cell lineage determination during gastrulation (45, 
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46)	   and brain development in vertebrates (47, 48). However, the function of this 
important transcriptional factor during HP axis development has not been investigated to 
date. Moreover, despite the solid evidence demonstrating the critical function of the 
WNT/β-catenin pathway during HP axis development in the mouse, so far mutations in 
components of this pathway have not been identified in patients with CH. In this 
manuscript we reveal that the β-catenin-independent repressor activity of TCF7L1 is 
required for normal HP axis formation in mice and humans.  
 
Materials and Methods 
 
Mice 
The Hesx1Cre/+ (49), Tcf7l1flox/flox (44) and Tcf7l1ΔN/ΔN (33) have been previously 
described. We have previously shown that the Hesx1-Cre mouse line drives efficient 
recombination of loxP-flanked DNA in RP progenitors from 9.5 dpc (49, 50). 
Hesx1Cre/+;R26loxP-YFP/+ 18.5 dpc embryos display widespread yellow fluorescent protein 
(YFP) expression in the vast majority of cells of the anterior pituitary, suggesting that the 
Hesx1-expressing RP progenitors give rise to all hormone-producing cells (Hesx1-cell 
lineage). In addition to RP, Hesx1Cre/+;R26loxP-YFP/+ and Hesx1Cre/+;R26loxP-lacZ/+ embryos 
show reporter expression in the ventral telencephalon and pre-optic hypothalamic area 
from 9.5 dpc (49-51). Tcf7l1 is expressed in the forebrain, including the hypothalamic 
area, as well as in the anterior pituitary until 14.5 dpc (37). To reveal the function of 
Tcf7l1 during normal HP axis development we used the Tcf7l1flox/flox conditional mouse 
line (44, 47). To generate pituitary-specific Tcf7l1 genetic deletions, Tcf7l1flox/flox mice 
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were initially crossed to β-actin:Cre animals  (52) to generate Tcf7l1+/- heterozygous mice. 
These mice were subsequently crossed to Hesx1Cre/+ to generate Hesx1Cre/+;Tcf7l1+/- 
double heterozygotes, which upon crossing with Tcf7l1flox/flox mice, were used to generate 
the Hesx1Cre/+;Tcf7l1flox/- mice and embryos analyzed in this study. Genotyping of mice 
and embryos was carried out by PCR on ear punch biopsies or pieces of tissue from 
embryos digested in DNAreleasy (Anachem) as per manufacturer’s instructions. The data 
presented in this work are representative of examples of at least 3 individual embryos per 
genotype. All the experiments performed in mice were carried out according to UK 
Home Office guidance and approved by a local ethical committee. 
 
Patient recruitment   
Patients with congenital hypopituitarism (CH) disorders were recruited into the study 
from both national and international pediatric and adult endocrinology centers between 
1998 and 2005. A total of 215 probands (129 male, 86 female) were screened for 
mutations within TCF7L1. These included 31 patients with CH without any midline or 
eye defects, 6 with holoprosencephaly (HPE), 148 patients with septo-optic dysplasia 
(SOD) (characterized by optic nerve hypoplasia in association with hypopituitarism 
and/or midline defects), and 30 patients with anophthalmia (n = 12) or microphthalmia (n 
= 18). Ethical committee approval was obtained from the Institute of Child Health/Great 
Ormond Street Hospital for Children Joint Research Ethics Committee (Institute of Child 
Health, London, United Kingdom). Informed written consent was obtained from the 
parents and, where applicable, the patients prior to collection of samples and genomic 
analysis. 
	   8	  
 
Mutation analysis of TCF7L1 
The entire coding region of TCF7L1 (NM_031283) was PCR-amplified and subjected to 
direct-sequencing in our cohort. Detailed PCR and sequencing conditions are available 
upon request. For any mutations identified, control databases were consulted including 
1000 Genomes (www.1000genomes.org),	   Single Nucleotide Polymorphism Database 
(dbSNP), Exome Variant Server (EVS) and the	  Exome Aggregation Consortium (ExAC; 
comprising >61,000 genomes) Browser (http://exac.broadinstitute.org/). Patients 1 and 2 
were screened and found not to carry mutations in other relevant genes involved in CH 
and SOD, specifically: Patient 1 was screened for mutations in HESX1, CHD7, KAL1, 
PROKR2, FGFR1 and FGF8; and Patient 2 in HESX1, SOX3, KAL1, PROKR2, FGFR1 
and FGF8.  
 
In situ hybridization on histological sections 
Histological processing of embryos and in situ hybridization on paraffin sections was 
performed as previously described (53, 54). The antisense riboprobes used in this study 
(Gh, Cga, Pomc1, Prop1, Lh, Tsh, Fgf10, Fgf8, Bmp4, Lhx3, Bmp4, Tbx2, Tbx3 and Pit1) 
have been described (51, 53-55). Human TCF7L1 riboprobe was generated using a full-
length cDNA cloned into pCMV-Sport6 (SalI 5’, NotI 3’) (SourceBioscience, clone 
number: IRATp970D0681D, IMAGE: #6141641). 
 
Immunohistochemistry 
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Embryos were fixed in 4% PFA and processed for immunodetection as previously 
described (11, 51). Detection of hormones was carried out using antibodies for α-ACTH 
(10C-CR1096M1), α-TSH (NHPP AFP-1274789), α-PRL (NHPP AFP-425-10-91), α-LH 
(NHPP AFP-C697071P) and α-FSH (AFP-7798-1289) (Developmental Studies 
Hybridoma Bank) at a 1:1000 dilution. α-SHH (AF464; R&D Systems) and α-TCF7L1 
(33) were used at a 1:100 dilution and signal amplified using the Tyramide Signal 
Amplification kit (Perkin Elmer, NEL741001KT). α-Cleaved Caspase 3 was used at a 
1:300 dilution (9661; Cell Signaling Technologies) and α-phosphorylated-histone H3 at a 
1:1000 dilution (06-570; Upstate). The mitotic index of pituitary periluminal progenitors 
represents the percentage of proliferating cells (phosphorylated-histone H3 positive cells) 
from total number of DAPI-positive nuclei. Anti-phosphorylated-histone H3 (1:1000) 
(rabbit polyclonal; Upstate) was used for this study.    
 
Cell transfection, luciferase assays and immunoblotting  
HEK293T cells were grown in DMEM supplemented with 10% fetal bovine serum. Two 
reporters were used to assess the repressing activity of human wild-type TCF7L1 and the 
p.R92P and p.R400Q variants: (1) the TOPflash reporter plasmid carrying six wild-type  
binding sites for the TCF/LEF1 factors upstream of the firefly luciferase gene; (2) the 
LEF1-promoter-luc reporter, which contains a DNA fragment (-6713 to -1 bp) of the 
human LEF1 promoter inserted upstream of a luciferase reporter gene (33). 
Approximately 250,000 cells were seeded per well of 24-well tissue culture plates and the 
following day subjected to DNA transfection. A total of 100 ng of TOPflash or 200 ng of 
LEF1-promoter-luc reporter were co-transfected with constructs expressing wild-type and 
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mutant hTCF7L1 proteins (10 and 50 ng) and 80 ng Renilla luciferase plasmid as internal 
control using Lipofectamine 2000 (Life Technologies) according to the manufacturer’s 
protocol. The total amount of DNA was kept constant in all the transfections by 
complementing with pBluescript plasmid up to 350 ng. Activation of the TOPflash 
reporter was achieved by culturing the cells in the presence of 10 µM SB216763 (Sigma), 
a potent GSK3-β inhibitor resulting in the stabilization of β-catenin. The LEF1-promoter-
luc was activated with 30 µM SB216763. The repressing activity of wild-type hTCF7L1 
and the variants was assessed 48 hours post-transfection using the Dual-Luciferase 
Reporter Assay System (Promega) following the manufacturer’s instructions. Total levels 
of repression caused by the hTCF7L1 p.R92P and p.R400Q proteins were represented as 
a percentage of the maximum repression caused by wild-type hTCF7L1. Experiments 
were repeated 4 times in triplicates and statistical analysis was done using one-way 
ANOVA with Tukey’s post-hoc analysis.  
 
Zebrafish Experiments 
Zebrafish were bred and raised under standard conditions. hdl/tcf7l1am881-/-;tcf7l1bzf157Tg+/- 
(from now on tcf7l1a-/-; tcf3l1b+/-) zebrafish embryos were generated from crossing 
tcf7l1a+/-;tcf7l1b+/- males with tcf7l1a+/- females (56), raised at 28°C and staged according 
to Kimmel et al. (57) Embryos were microinjected with 100 picograms (5 nanoliters) of 
mRNA encoding either wild-type, p.R92P or p.R400Q hTCF7L1 at one to two cell stage. 
mRNA encoding wild-type or mutant hTCF7L1 proteins was co-injected with mRNA 
encoding GFP, and embryos with low or no GFP fluorescence were excluded from the 
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analysis. tcf7l1a  alleles were genotyped by KASP assays (LCG Group). The tcf7l1b viral 
insertion was identified by genomic DNA PCR using the following primers:  
GSP2-F: 5’-GGATACCGTGTGATCGTTTCTC-3’ ; and LTR2-R: 5’-
TCTGTTCCTGACCTTGATCTGA -3’. 
 
Statistics 
Mendelian ratios were evaluated using the chi-squared test. For all other analyses, a one-
way ANOVA was utilised. Values less than 0.05 were considered statistically significant. 
Quantitative data are presented as mean ± standard error of the mean (SEM). Clonogenic 
potential of control and Hesx1Cre/+;Tcf7l1+/- mutant stem cells was evaluated using a 
paired t-test. Total cell counts of control and Hesx1Cre/+;Tcf7l1+/- mutant pituitaries were 
analyzed by unpaired t-test. 
 
Results 
Hesx1Cre/+;Tcf7l1flox/- mutants exhibit forebrain and pituitary defects  
Genotyping analysis of 9.5-18.5 dpc embryos from crosses between Hesx1Cre/+;Tcf7l1+/- 
and Tcf7l1flox/flox showed a normal Mendelian distribution of genotypes, implying that the 
lack of Tcf7l1 in the Hesx1-cell lineage is not embryonic lethal (Table 1). 
Hesx1Cre/+;Tcf7l1flox/- mutant embryos displayed variable degrees of  anterior forebrain 
defects, including eye defects (i.e. microphthalmia or anophthalmia) and telencephalic 
abnormalities (i.e. small or absent telencephalic vesicles), as previously described (47) 
(Fig. S1C). Additionally, we observed neural tube closure defects resulting in 
exencephaly in around 10% of these mutants (Fig. S1B). Genotyping analyses of mice at 
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3 weeks of age revealed no significant differences of the expected Mendelian ratios for 
the Hesx1Cre/+;Tcf7l1flox/- mutants when compared with control littermates, but perinatal 
death was observed in some Hesx1Cre/+;Tcf7l1flox/- mice (Table 1). Most of the surviving 
mutants did not exhibit any gross morphological defects, but around 25% of these 
showed dwarfism with reduced size and weight compared with their littermates, 
suggesting a potential functional compromise of the HP axis (Fig. S1A, D and E). We 
observed unilateral microphthalmia with no compromise of the telencephalic vesicles in 
around 20% of the Hesx1Cre/+;Tcf7l1flox/+ embryos as previously reported (47).  
Histological and in situ hybridization analyses of Hesx1Cre/+;Tcf7l1flox/- mutant and 
control embryos at 17.5 dpc revealed two clearly discernable pituitary phenotypes: (i) 
Group 1 embryos, approximately 25% of the Hesx1Cre/+;Tcf7l1flox/- mutants, displayed 
severe morphological defects and ectopic pituitary tissue was often observed in the roof 
of the oropharyngeal cavity (Fig. 1A’’-H’’). In these mutants, morphologically 
distinguishable posterior or intermediate lobes could not be observed. This phenotype 
was associated with severe forebrain defects. Hormone-producing cells were detected in 
these mutants, even in the ectopically located pituitary tissue; (ii) Group 2 embryos, 
accounting for approximately 75% of Hesx1Cre/+;Tcf7l1flox/- mutants, showed a less severe 
phenotype with mild pituitary hyperplasia and presence of pituitary cleft bifurcations  
(Fig. 1D’-H’). Posterior and intermediate lobes appeared morphologically normal in 
mutants in this group. Total cell counting of dissociated pituitaries at 18.5 dpc revealed 
average cell counts of 75,300 ± 5227.33 for the Hesx1Cre/+;Tcf7l1flox/- mutants (n=5) and 
66,200 ± 7585.62 for controls (n=8). Although these differences did not reach statistical 
significance (p=0.0584), the data suggest a trend towards mild hyperplasia in Group 2 
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mutants. Differentiation of hormone-producing cells occurred normally with no apparent 
differences between Hesx1Cre/+;Tcf7l1flox/- Group 2 mutants and control embryos. The 
Sox2-positive stem cell compartment was analyzed in vitro by culturing dissociated cells 
in stem cell-promoting medium, which revealed no differences in clonogenic potential 
between Group 2 mutants and controls (Fig. S2). 
Similar morphological abnormalities, including hyperplasia, cleft bifurcations and 
ectopically located pituitary tissue, were observed in Hesx1Cre/+;Tcf7l1flox/- mutants at 
13.5 and 15.5 dpc. Nevertheless, expression of Lhx3, Pomc1, Prop1 and Pit1 at 13.5 dpc 
as well as Lhx3, Pomc1, Cga and Pit1 at 15.5 dpc was detected in the developing 
pituitary of all mutants analyzed (Fig. 2A-P). Together, these analyses suggest that loss of 
Tcf7l1 in Hesx1-expressing cells leads to aberrant pituitary morphogenesis but normal 
cell differentiation in the majority of the embryos, with low penetrance of a phenotype 
characterized by ectopic pituitary tissue, possibly of anterior lobe identity, in the 
oropharyngeal cavity concomitant with defective terminal differentiation. 
 
Abnormal hypothalamic signaling and increased proliferation of Rathke’s pouch 
progenitors in Hesx1Cre/+;Tcf7l1flox/- mutants 
During early pituitary development, the synergistic expression of Bmp4, Fgf8 and Fgf10 
within the developing hypothalamus is essential for the induction of Lhx3 in the region of 
the oral ectoderm fated to become Rathke’s pouch (RP) (2). The expression domains of 
Fgf8, Fgf10 and Bmp4 in the hypothalamic anlage (Fig. 3A-L), and of Lhx3 in the 
underlying RP (Fig. 3M-P), were rostrally expanded in the Hesx1Cre/+;Tcf7l1flox/- mutants 
relative to controls at 9.5 dpc. Enlargement of the Lhx3-expression domain suggests the 
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recruitment of additional oral ectoderm into Rathke’s pouch epithelium, which may 
contribute to the hyperplasia observed at subsequent developmental stages. The 
expression of SHH, another critical signal required for normal RP development (58, 59), 
in the preoptic area of the hypothalamus was shifted anteriorly and slightly reduced in the 
Hesx1Cre/+;Tcf7l1flox/- mutants in comparison with controls (Fig. 4I-L). In agreement with 
this observation, the expression domains of Tbx3, and to a lesser extent Tbx2, which 
normally act as repressors of Shh expression in the hypothalamus (55), were rostrally 
shifted thus invading the caudal region of the preoptic area, where SHH expression 
appears reduced (Fig. 4A-H). 
Proliferation analysis revealed a mild but statistically significant increase in the 
mitotic index of RP periluminal progenitors in Hesx1Cre/+;Tcf7l1flox/- mutant pituitaries at 
13.5 dpc (p <0.05), but this was transient and not observed at 15.5 dpc (p >0.05)  (Fig. 
2Q-S). This phenotype is entirely consistent with the deletion of Tcf7l1 in both the 
hypothalamus and RP in the Hesx1Cre/+;Tcf7l1flox/- mutant pituitaries (Fig. S3C and D). 
Caspase 3 immunostaining revealed the presence of a few apoptotic cells in the ventral 
regions of RP in both the mutant and control embryos (Fig. S3A and B). Together, these 
studies suggest that Tcf7l1 is required for proper patterning of the prospective 
hypothalamus and for establishment of the normal expression domains of critical 
hypothalamic signals involved in the induction and proliferation of RP progenitors.  
 
TCF7L1 functions as a repressor during normal pituitary organogenesis  
Next, we sought to assess whether the requirement of TCF7L1 within the developing 
hypothalamus and pituitary gland was dependent or independent of β-catenin. To achieve 
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this, we used a recently generated mouse line (Tcf7l1ΔN/ΔN) expressing a TCF7L1 mutant 
protein lacking the β-catenin-interacting domain at the N-terminus. This truncated form 
of TCF7L1 (TCF7L1ΔN) shows similar DNA binding and repressing activities to wild-
type TCF7L1, but its interaction with β-catenin is abolished (33).  
In situ hybridization analysis revealed the absence of morphological defects in the 
pituitary gland and the normal expression of terminal differentiation markers (Gh, Pomc, 
Cga, Tsh and Lh) in Tcf7l1ΔN/ΔN mutants relative to control embryos at 18.5 dpc (Fig. 5I-
R). Likewise, the expression domain of Fgf10 within the hypothalamus and Lhx3 in the 
developing RP were comparable between genotypes (Fig. 5A-H). Note that Tcf7l1ΔN/ΔN 
mutants show a general developmental delay and are smaller than control littermates, 
which accounts for the slight size differences in the expression domains (Fig. 5C and D) 
(33). The absence of any apparent defects in Tcf7l1ΔN/ΔN mutants demonstrates that 
TCF7L1 acts primarily as a transcriptional repressor within the developing hypothalamus 
and pituitary gland and that its function is independent of β-catenin. Additionally, these 
data imply that the defects observed in Hesx1Cre/+;Tcf7l1flox/- mutants are a consequence 
of the de-repression of TCF7L1 transcriptional targets. 
 
Variants in TCF7L1 are associated with forebrain and pituitary defects in humans 
The forebrain and pituitary defects observed in the Hesx1Cre/+;Tcf7l1flox/- mutants are very 
similar to those previously described in Hesx1-deficient embryos, suggesting that these 
transcriptional repressors may control the same genetic program (49, 54). Since 
mutations in HESX1 have been associated with congenital hypopituitarism in humans, 
including SOD (60, 61), we hypothesized that mutations in TCF7L1 may also be 
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implicated in these conditions. Indeed, in situ hybridization showed that TCF7L1 is 
expressed during human embryonic development within brain tissue, including the 
hypothalamus, and the developing pituitary gland (Fig. 6).  
To investigate this possibility, we screened a total of 215 patients with 
hypopituitarism including SOD for mutations in the TCF7L1 locus by Sanger sequencing. 
Two heterozygous sequence variants resulting in amino acid changes in highly conserved 
residues of TCF7L1 were identified in two unrelated patients (clinical details are 
presented in Table 2 and SI). 
Patient 1 of Caucasian (Finnish; non-consanguineous) descent, showing forebrain 
defects (i.e. partial agenesis of the corpus callosum, thin right optic tract and thin anterior 
commissure), and normal pituitary function, carried a missense G to C sequence variant 
at position 275 (c.275G>C), which causes the substitution of arginine 92 by proline 
(p.R92P) (Fig. 7A and B). This variant was not identified in online databases (listed 
previously) or 392 additional Caucasian controls (including 200 healthy Finnish).  The 
variant was inherited from the father, and was also present in the paternal uncle, who 
were both asymptomatic. 
Patient 2, of Pakistani (non-consanguineous) descent, was diagnosed with 
classical SOD and showed small optic nerves and chiasm, an absent posterior pituitary, a 
very small anterior pituitary and absent septum pellucidum. The proband harbored a 
missense G to A sequence variant (c.1199G>A) resulting in an arginine to glutamine 
change at position 400 (p.R400Q) (Fig. 7A and B). Although this variant was not 
identified in our healthy controls, the dbSNP or the ESP databases, it is present in 14 
individuals in the ExAC database with an allelic frequency of 2.958e-05, in 
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heterozygosity. The variant was inherited from the unaffected mother, and 2 unaffected 
siblings also carried the variant. 
 
TCF7L1 p.R92P and  p.R400Q variants show impaired repressing activity in vitro 
and in vivo 
We sought to assess the capacity of wild-type and hTCF7L1 p.R92P and  p.R400Q 
proteins to repress WNT/β-catenin-mediated transcriptional activation in vitro.  We used 
two different reporters in transfected HEK293 cells cultured in the presence of a GSK3β 
inhibitor. Using the TOPflash reporter, the repressing activity of the TCF7L1 (p.R92P) 
variant was reduced by 34% - 40% (10 ng and 50 ng, respectively; p<0.05) relative to 
wild-type TCF7L1 (Fig. 7C, left graph). Likewise, the repressing activity of the TCF7L1 
(p.R400Q) variant on the TOPflash reporter was diminished by 41% - 55% (10 ng and 50 
ng, respectively; p<0.05) compared with wild-type TCF7L1 (Fig. 7C, left graph). A 
reduction of the transcriptional repressing activity of these variants was also observed 
when using the hLEF1-promoter-luc reporter (30% reduction for TCF7L1 (p.R92P) and 
27% reduction for the TCF7L1 (p.R400Q) (p <0.05)) (Fig. 7C, right graph). In these 
transfection experiments wild-type and mutant hTCF7L1 proteins were expressed at 
similar levels, as revealed by western blot analysis using a specific anti-TCF7L1 antibody 
(Fig. 7D). No dominant-negative effects were observed in co-transfection experiments 
combining wild-type and hTCF7L1 p.R92P and p.R400Q variants  (Fig. S4). 
Finally, to assess the repressing activities of the two variants in vivo, we took 
advantage of a zebrafish model with a lower gene dosage of the hTCF7L1 orthologues 
tcf7l1a and tcf7l1b. tcf7l1a-/- and tcf3l1b+/- single mutants show no phenotype, but tcf7l1a-
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/-;tcf3l1b+/-  double mutants exhibit an eyeless phenotype due to the ectopic activation of 
the Wnt/β-catenin signalling pathway and de-repression of targets of this pathway in the 
forebrain (including the eye field) (30, 31). We injected double tcf7l1a-/-;tcf7l1b+/- double 
mutant zebrafish embryos, which normally develop no eyes, with mRNA encoding either 
wild-type hTCF7L1 or the two variants identified aiming to determine their ability to 
rescue the eyeless phenotype. Microinjection of wild-type hTCF7L1 mRNA fully rescued 
the eyeless phenotype of tcf7l1a-/-;tcf3l1b+/- double mutants (Fig. 8; n=18 mutants, 3 
independent experiments). However, only 67.7% (21 out of 31 mutants) and 50% (12 out 
of 24 mutants) of the eyeless tcf7l1a-/-;tcf3l1b+/- embryos were rescued by injection of 
mRNA encoding the p.R92P and p.R400Q hTCF7L1 variants, respectively (Fig. 8). 
These results support the in vitro findings previously presented and add further evidence 
to the notion that the hTCF7L1 variants p.R92P and p.R400Q exhibit reduced repressing 
activity in vivo.  
 
Discussion 
In this manuscript we have provided genetic and molecular evidence demonstrating that 
the repressing activity of the transcription factor TCF7L1 is required for normal 
establishment of the HP axis in mice and humans.  
The pituitary defects of the Hesx1Cre/+;Tcf7l1flox/-  mouse mutants are very similar 
to those observed in Hesx1-/- embryos; increased proliferation leading to abnormal 
pituitary morphogenesis but overall normal terminal differentiation (14, 54). We show 
the absence of mTCF7L1 protein in both the hypothalamus and the developing RP by 
10.5 dpc in Hesx1Cre/+;Tcf7l1fl/- mutants, thus validating the genetic approach. Within the 
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hypothalamus, we have revealed a critical role for mTCF7L1 in the regulation of antero-
posterior patterning, as there is an overall anterior shift in the expression domains of 
caudal hypothalamic signals and markers (e.g. Fgf8, Fgf10, Bmp4, Tbx2 and Tbx3), 
which is concomitant with a reduction in SHH expression in the anterior hypothalamic 
area (Fig. 3 and 4). This abnormal hypothalamic signaling results in the recruitment of 
additional ectoderm into RP, as detected by the rostral expansion in the Lhx3 expression 
domain and increased proliferation in the developing pituitary of Hesx1Cre/+;Tcf7l1fl/- 
mutants at 13.5 dpc. In addition, there may be a contribution to the phenotype due to the 
lack of TCF7l1 within RP, which we cannot rule out.  
There is a marked variability of expressivity of the pituitary phenotype in 
Hesx1Cre/+;Tcf7l1fl/- mouse mutants (Fig. 1 and 2), which is reminiscent of that observed 
in Hesx1-deficient embryos. In most of the Hesx1Cre/+;Tcf7l1fl/- mutants (Group 2), there 
is an overall increase in pituitary tissue and anterior, posterior and intermediate lobes can 
be identified. However, in the most severely affected mutants (Group 1), the posterior 
and intermediate lobes cannot be morphologically detected from 13.5 to 17.5 dpc. 
Incidentally, some Hesx1Cre/+;Tcf7l1fl/- mutants at 9.5 dpc show a lack of contact between 
the developing infundibulum and RP, which may contribute to the development of the 
ectopic pituitary in the roof of the oropharyngeal cavity. It is likely that this phenotypic 
variability observed from 13.5 dpc, is brought about by the differential dysregulation of 
the hypothalamic signals normally involved in induction and proliferation of RP 
progenitors, an idea that is difficult to test experimentally. 
Previously, we have shown that the cooperation between HESX1 and TCF7L1 is 
required to repress the activation of the WNT/β-catenin pathway in the anterior neural 
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plate of zebrafish and mouse embryos (47). Our data are in support of the idea that 
TCF7L1 acts as a repressor during normal pituitary development in mice. Functional 
studies in mice have demonstrated a temporally specific function of the WNT/β-catenin 
signaling pathway during pituitary organogenesis. This pathway must be repressed at 
early stages of pituitary development and activated from 14.5 dpc for normal 
differentiation of the Pou1f1-cell lineage (37). In agreement with this notion, the 
permanent activation of the WNT/β-catenin pathway in RP progenitors at 9.5 dpc, by 
expression of a degradation-resistant form of β-catenin, results in severe pituitary 
hyperplasia during embryogenesis (50). Mice deficient for Tcf7l2, a TCF/LEF factor 
shown to act as either an activator or a repressor depending on the cell context, show 
anterior pituitary hyperplasia but no defects in the differentiation of hormone-producing 
cells (41). The similarities in the pituitary phenotype between Tcf7l2-/-, Hesx1-/- and 
Hesx1Cre/+;Tcf7l1flox/- mutants suggest that these factors are likely to act as transcriptional 
repressors of WNT/β-catenin pathway targets during HP axis development. Indeed, the 
expression of a mutant form of TCF7L1 unable to interact with β-catenin, but 
maintaining repressing activity, does not lead to any hypothalamic or pituitary defects, 
demonstrating that TCF7L1 is required as a repressor (Fig. 5).  
 Our data also provide evidence that the repressing activity of TCF7L1 is required 
for normal HP axis development in humans. Firstly, we show the expression of hTCF7L1 
mRNA in the developing human embryo (Fig. 6). Furthermore, we have identified two 
TCF7L1 variants, p.R92P and p.R400Q, in unrelated families with SOD, which substitute 
highly conserved residues, and shown that these variants are functionally compromised.  
These mutant proteins show reduced repressing activity relative to wild-type TCF7L1 
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using both the TOPflash reporter plasmid and a luciferase reporter containing a fragment 
of the human LEF1 promoter (Fig. 7) (33). In addition, we show that the TCF7L1 p.R92P 
and p.R400Q variants cannot rescue the eye defects of zebrafish mutants with a reduced 
gene dosage of tcf7l1 (Fig. 8). Given the presence of the variants in the phenotypically 
unaffected father and paternal uncle, our data suggest that they are not uniquely 
responsible for disease development, but may be variably penetrant. The concept of 
variable penetrance has been observed in a variety of human genetic disorders. These 
include Kallmann syndrome, where recent data have suggested an oligogenic basis to the 
disorder (62). Additionally, mutations in SHH and GLI2, a mediator of SHH, are 
associated with variably penetrant holoprosencephaly. Sequence variants in LHX4 and 
GLI2 are also associated with variably penetrant CH (63, 64). Of note, variable 
phenotypic expressivity is also observed in the Hesx1Cre/+;Tcf7l1fl/- mouse mutants and in 
the tcf7l1a-/-;tcf3l1b+/- zebrafish mutants injected with the hTCF7L1 variants identified in 
this study. 
In summary, we identify Tcf7l1 as a novel determinant for the establishment of 
the HP axis and as a potential candidate gene to be mutated in congenital 
hypopituitarism. 
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Figure Legends 
Figure 1. Abnormal pituitary morphogenesis in Hesx1Cre/+;Tcf7l1fl/- mutants. In situ 
hybridization (A-C) and immunohistochemistry (D-H) of transverse histological sections 
of the pituitary gland of control embryos (A-H) and Hesx1Cre/+;Tcf7l1fl/- mutants (A’-H’ 
and A’’-H’’) at 17.5 dpc.  (A’-H’) Mildly affected embryos show pituitary hyperplasia, 
cleft bifurcations (arrows in D’ and E’), but mostly normal expression of differentiation 
markers. (A’’-H’’) Severely affected pituitaries exhibit dysmorphic pituitary tissue that is 
ectopically located in the oropharyngeal cavity (arrowheads) but hormone-producing 
cells are present. Abbreviations:  AP anterior pituitary; BS basisphenoid bone; OC oral 
cavity; PP posterior pituitary; Gh, growth hormone; Pomc1, pro-opiomelanocortin-alpha; 
ACTH, adrenocorticotroph hormone; TSH, thyroid stimulating hormone; FSH, follicle 
stimulating hormone; LH, luteinising hormone; Cga, glycoprotein hormone alpha. 
Pictures are representative of 5 embryos per genotype. Scale bar in H” is 100 µm. 
 
Figure 2. Increased proliferation of Rathke’s pouch progenitors but normal 
patterning of the developing anterior pituitary in Hesx1Cre/+;Tcf7l1fl/- mutants. (A-P) 
In situ hybridization on sagittal sections through the pituitary gland of control and 
Hesx1Cre/+;Tcf7l1fl/- mutant embryos (stage and probes are indicated; anterior to the left). 
(A-H) Mildly affected pituitaries show bifurcations and moderate expansion of the 
expression domains of Lhx3 and Prop1 at 13.5 and 15.5 dpc (arrows). (I-P) Severely 
affected pituitaries exhibit enlarged expression domains due to the abnormal 
morphogenesis of the developing anterior pituitary, which extends into the oropharyngeal 
cavity (arrowheads). (Q-R) Anti-phospho-histone H3 immunofluorescent staining on 
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sagittal histological sections of a control embryo and a Hesx1Cre/+;Tcf7l1fl/- mutant.  
Quantitative analyses showing a statistically significant increase in the mitotic index in 
the Hesx1Cre/+;Tcf7l1fl/-  developing pituitaries relative to control littermates at 13.5 dpc 
but not at 15.5 dpc. Abbreviations: AP, anterior pituitary; BS, basisphenoid bone; Inf, 
infundibulum; OC oropharyngeal cavity. Pictures are representative of 7 embryos per 
genotype. ***p< 0.05, one way ANOVA. Scale bar: H and P, 100 µm.  
 
Figure 3. Dysregulation of Fgf8, Fgf10 and Bmp4 expression in the hypothalamus of 
Hesx1Cre/+;Tcf7l1fl/- mutants. In situ hybridization on sagittal histological sections 
revealing the expression of Fgf10 (A-D), Fgf8 (E-H) and Bmp4 (I-L) in the prospective 
hypothalamus and Lhx3 (M-P) in Rathke’s pouch (anterior to the left). (A-H) Fgf10 and 
Fgf8 expression domains are anteriorized along the neural epithelium of the ventral 
diencephalon (i.e. prospective hypothalamus) overlaying the oral ectoderm of RP in the 
Hesx1Cre/+;Tcf7l1fl/- mutants (compare arrowheads in C and D and G and H, respectively). 
C and D and G and H represent enlarged images of the dotted squared areas in A and B 
and E and F, respectively. (I-L) The expression domain of Bmp4 is rostrally expanded in 
Hesx1Cre/+;Tcf7l1fl/- prospective hypothalamus compared with control embryos (compare 
arrowheads K and L). K and L represent enlarged images of the squared dotted areas in I 
and J. (M-P) The expression domain of Lhx3 is rostrally extended in Hesx1Cre/+;Tcf3fl/- 
compared to the control embryo (arrows in O and P), indicating an expansion of the RP 
epithelium. O and P are enlarged images of the dotted square areas in M and N 
respectively. Abbreviations: VD, ventral diencephalon; RP, Rathke’s pouch. Pictures are 
representative of 5 embryos per genotype. Scale bar in P is 100 µm.  
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Figure 4. SHH and its regulators Tbx2 and Tbx3 are mis-expressed in the developing 
hypothalamus of Hesx1Cre/+;Tcf7l1fl/- mutants. (A-H) In situ hybridization on sagittal 
sections of 10.5 dpc embryos (anterior to the left) reveals the anterior shift of the Tbx3 
expression domain, and to a lesser extent Tbx2, within the developing hypothalamus of 
the Hesx1Cre/+;Tcf7l1fl/- mutants compared with the control embryos. (I-L) 
Immunostaining showing a reduction of SHH expression in the caudal region of the pre-
optic area in a Hesx1Cre/+;Tcf7l1fl/- mutant relative to a control. Note that the reduction of 
SHH expression in the caudal region of the preoptic area appears to overlap with the 
anterior extension of Tbx3 expression. Abbreviations: VD, ventral diencephalon; RP, 
Rathke’s pouch. Pictures are representative of 3 embryos per genotype. Scale bar in P is 
100 µm.  
 
Figure 5.  Expression of a mutant form of TCF7L1 lacking the β-catenin-interacting 
domain (Tcf7l1ΔN/ΔN) is sufficient to sustain normal hypothalamic-pituitary axis 
development. (A-H) In situ hybridization on sagittal sections showing normal expression 
domains of Fgf10 (A-D) and Lhx3 (E-H) in Tcf7l1ΔN/ΔN mutants and control wild-type 
littermates at 9.5 dpc (anterior to the left). C, D, G and H are enlarged images of the 
dotted squared areas. The apparent difference in size in the Tcf7l1ΔN/ΔN mutants relative to 
the controls is caused by an overall developmental delay in the mutants. (I-R) In situ 
hybridization on transverse histological sections through the pituitary gland of Tcf7l1ΔN/ΔN 
mutants and control embryos at 18.5 dpc reveal no gross differences in the levels of 
expression of several differentiation markers. Note that pituitary morphogenesis is also 
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normal in Tcf7l1ΔN/ΔN mutants relative to controls. Abbreviations: AL, anterior lobe; BS, 
basisphenoid bone; VD, ventral diencephalon; RP, Rathke’s pouch; PL, posterior lobe. 
Pictures are representative of 5 embryos per genotype. Scale bars: H and R, 100 µm.  
 
Figure 6. TCF7L1 is expressed in the developing hypothalamic-pituitary axis, 
central nervous system and eyes during human embryogenesis. In situ hybridization 
against hTCF7L1 on coronal (A-C and G-I) or sagittal (D-F) histological sections at 
Carnegie Stage (CS) 13, 18 and 20. (A-C) Note the expression of hTCF7L1 in the ventral 
diencephalon (VD)) neuroepithelium (i.e. prospective hypothalamus (arrowheads in B), 
Rathke’s pouch progenitors (arrows in B) and developing optic cups (OC; arrows in C) at 
CS13. (D-F) At CS18 expression of hTCF7L1 is observed throughout the 
neuroepithelium of the hind-, mid- and forebrain, including the hypothalamus 
(arrowheads in E) and telencephalon (arrows in F). Expression is also detected in the 
developing anterior pituitary gland (AP) (arrows in E). (G-I) At CS20 expression of 
hTCF7L1 is detected in the anterior and posterior lobes of the pituitary gland (AP and PP 
in H), neural retina (NR) (arrows in I), eyelid (arrow in G), olfactory epithelium of the 
nasal cavity (NC) and trigeminal ganglia. B ,C, E, F, H, I are enlarged images of the 
dotted squared areas.  Abbreviations: VD ventral diencephalon; RP Rathke’s pouch; OC 
optic cup; AP anterior pituitary; hyp hypothalamus;  AP anterior pituitary; PP posterior 
pituitary; BS basisphenoid bone;  NR neural retina; ON optic nerve. Scale bars: in A, D 
and G are 500 µm; in B-C, E-F and H-I are 100 µm.    
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Figure 7. Identification of hTCF7L1 heterozygous missense variants in patients with 
septo-optic dysplasia. (A) Electropherogram showing two novel heterozygous missense 
variants in hTCF7L1: p.R92P and p.R400Q.  (B) Both DNA variants result in the 
substitution of highly conserved amino acids. R92 is not conserved in Xenopus and 
zebrafish. (C) Transient luciferase assays on HEK293 cells co-transfected with either 
TOPflash (left graph) or hLEF1-promoter-luc (right graph) reporters and constructs 
expressing wild-type, p.R92P or p.R400Q hTCF7L1 proteins. Note the significant 
reduction in repressing activity of the p.R92P and p.R400Q hTCF7L1 variants relative to 
wild-type TCF7L1 using both reporters. ** p<0.05 one way ANOVA. (D) Western blot 
analysis of transfected HEK293 cells used in (C) with a specific anti-TCF7L1 antibody 
detects the expression of the wild-type and p.R92P or p.R400Q hTCF7L1 proteins at 
similar levels. GAPDH was also detected in the same membrane as loading control. 
 
Figure 8. Incomplete rescue of the eyeless phenotype of double tcf7l1a/b zebrafish 
mutants with the human hTCF7L1 p.R92P and p.R400Q variants. Lateral view of 32 
hours post fertilisation zebrafish embryos (anterior to left). Wild-type embryos injected 
with 100 picograms of hTCF7L1 (C), p.R92P (E) and p.R400Q (H) mRNA show no 
phenotype compared with wild-type untreated embryos (A). tcf7l1a-/-;tcf3l1b+/- double 
mutants fail to develop eyes (B). Injection of tcf7l1a-/-;tcf3l1b+/- double mutants with 100 
picograms of wild-type hTCFL1 mRNA rescues the eyeless phenotype (D). Injection of 
tcf7l1a-/-;tcf3l1b+/- double mutants with 100 picograms of hTCF7L1 p.R92P (F, G) or  
p.R400Q (I, J) results in incomplete rescue of the eyeless phenotype. (K). Percentage of 
embryos with normal eyes is shown in blue and with very small or no eyes in red. 








